JNJ-26070109 is a high-affinity, competitive, orally active, and selective cholecystokinin 2 (CCK2) receptor antagonist; it is used as a research tool for gastroesophageal reflux disease (GERD) due to the dual role of CCK2 receptors in regulating gastric acid secretion and gastrointestinal mucosal growth.